First Author: C.Calvo SPAIN
Co Author(s): M. Jimenez J. Fernandez-Vigo J. Reche I. Flores
Back to previous
To compare the long term visual outcomes of two different initial dosing regimens of intravitreal ranibizumab used to treat myopic choroidal neovascularization (CNV)
retrospective, nonrandomized, consecutive, interventional case series study conducted on 61 eyes of 56 patients.
61 eyes of 56 patients with CNV secondary to pathologic myopia treated with intravitreal ranibizumab were retrospectively analyzed. In 26 eyes, treatment was a single injection and further treatment was given pro re nata (group 1+ PRN) while the remaining 35 eyes first received three consecutive monthly injections followed by further treatment PRN (group 3+ PRN). In each participant, demographic data, best-corrected visual acuity (BCVA), CNV recurrence and total number of injections were recorded.
Mean follow up was 53 ± 16 (24 - 91 months). BCVA values were 51.9 ± 16.2 letters in 3+ PRN and 53 ± 22.4 letters in 1+ PRN at baseline (p=0.824), and 69.5 ± 12.3 and 69 ± 15.1 letters respectively at 12 months, 66.6 ±16.5 and 67.7 ± 13.6 letters at 24 months, and 67.1 ± 16.2 and 66.4 ± 19.7 letters at end follow up, with no differences detected between groups (p=0.877). Also respectively for groups 3+ PRN and 1+ PRN, mean number of injections was 6.1 ± 4.1 and 3.2 ± 2.1, and mean survival until first retreatment was 36.9 ± 6.1 and 19.2 ± 5.4 months (both p<0.001). Baseline BCVA, age, number of injections and CNV location emerged as predictors of final BCVA (all p<0.05).
The two dosing regimens gave rise to similar visual outcomes. However, in eyes given a single initial injection, retreatment was needed appreciably earlier.